Back to News
Market Impact: 0.3
PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
PTC Therapeutics completed its previously announced acquisition of ST-920 from Sangamo Therapeutics. ST-920 is an investigational, BLA-stage AAV gene therapy for Fabry disease, adding a late-stage rare-disease asset to PTC's pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
PTCT0.55
SGMOQ0.40
More News
- Paramount will need to release way more movies to make this merger work
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Royal Caribbean nears $3 billion deal to take 50% equity stake in Sandals
- ACCC blocks IAG’s proposed acquisition of RAC Insurance
- Activist Jana Partners calls for Six Flags sale- WSJ